Comparison of 99mTc-alafosfalin and 67Ga-citrate in a mouse model of bacterial infection.

BACKGROUND The antibiotic-peptide (99m)Tc-alafosfalin was assessed as an infection imaging agent in Staphylococcus aureas infected mice by comparison with (99m)Ga-citrate, and also examined for influence of septic status on tracer biodistribution by comparison with normal mice. MATERIAL AND METHODS Intramuscular doses of S. aureus were administered into the right thigh muscle of mice and the infection was allowed to develop for 20 hours. In separate experiments, (99m)Tc-alafosfalin and (67)Ga-citrate were subsequently administered and allowed to localise. Quantitative organ distribution studies were performed in conjunction with scintigraphic images at 1 and 4 hours post injection. An additional biodistribution with (99m)Tc-alafosfalin in normal mice was also performed. RESULTS (99m)Tc-alafosfalin was predominantly renal excreted, with low liver, intestine and bone uptake. There was no difference in the uptake of these organs when infected mice were compared with normal mice. (99m)Tc-alafosfalin activity in the intestine at 1 and 4 hours was substantially less than (67)Ga-citrate. For (99m)Tc-alafosfalin, infected/non-infected thigh ratios of 2.8/1.0 and 3.6/1.0 were determined at 1 and 4 hours post injection respectively. (67)Ga-citrate gave ratios of 1.6/1.0 and 3.7/1.0 at the corresponding time points. CONCLUSIONS (99m)Tc-alafosfalin uptake was more rapid than (67)Ga-citrate, yet diffuse at the infectious sites in mice. The small and juvenile mouse model resulted in uptake of the phosphonic acid tracer by active bone growth areas which may be a disadvantage. This (99m)Tc-antibiotic peptide has potential as an infection imaging agent, and will be investigated further in another rodent infection model in the future.

[1]  F. Bartholomeusz,et al.  99mTc-alafosfalin: an antibiotic peptide infection imaging agent. , 2003, Nuclear medicine and biology.

[2]  E. Pauwels,et al.  Scintigraphic head-to-head comparison between 99mTc-WBCs and 99mTc-LeukoScan in the evaluation of inflammatory bowel disease: a pilot study , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  M. Thakur,et al.  Imaging infection with LeuTech® , 2001, Nuclear medicine communications.

[4]  D. Wareham,et al.  Technetium-99m labelled antimicrobial peptides discriminate between bacterial infections and sterile inflammations , 2000, European Journal of Nuclear Medicine.

[5]  F. Bartholomeusz,et al.  15. 99Tcm-Alafosfalin: A potential new antibiotic peptide for imaging bacterial infection , 2000 .

[6]  E. Pauwels,et al.  Technetium-99m labelled antimicrobial peptides discriminate between bacterial infections and sterile inflammations , 2000, European Journal of Nuclear Medicine.

[7]  E. Pauwels,et al.  Concerns about 99mTc-labelled ciprofloxacin for infection detection , 2000, European Journal of Nuclear Medicine.

[8]  E. Pauwels,et al.  Radiolabelled antimicrobial peptides for imaging of infections: a review. , 1998, Nuclear medicine communications.

[9]  P. H. Cox Radiopharmaceuticals for Imaging Infectious and Inflammatory Foci , 1998 .

[10]  J. Bomanji,et al.  Comparison of 99mTc Infecton imaging with radiolabelled white-cell imaging in the evaluation of bacterial infection , 1996, The Lancet.

[11]  M. Puncher,et al.  Labelling of leucocytes with colloidal technetium-99m-SnF2 , 1995 .

[12]  A. Peters The utility of [99mTc]HMPAO-leukocytes for imaging infection. , 1994, Seminars in nuclear medicine.

[13]  J. Perry,et al.  Radiopharmaceuticals in Nuclear Medicine Practice , 1987 .

[14]  S. W. Holmes,et al.  Phosphonopeptides as Antibacterial Agents: Alaphosphin and Related Phosphonopeptides , 1979, Antimicrobial Agents and Chemotherapy.

[15]  M. Thakur,et al.  Survey of radioactive agents for in vitro labeling of phagocytic leukocytes. I. Soluble agents. , 1976, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.